AI in Pathology Market Poised to Reach USD 347.4 Million by 2030 Amid Rapid Advances in Digital Diagnostics

Artificial intelligence (AI) is transforming pathology by enabling faster, more accurate, and highly scalable diagnostic processes. As healthcare systems worldwide embrace digital technologies, AI-powered pathology solutions are becoming indispensable for disease detection, image interpretation, clinical decision support, and drug development.

According to a recent MarketsandMarkets report, the global AI in Pathology Market is projected to grow from USD 107.4 million in 2025 to USD 347.4 million by 2030, registering an impressive CAGR of 26.5% during the forecast period. The market's expansion is being driven by rapid advancements in neural networks, growing adoption of digital pathology platforms, and increasing demand for precision medicine.

Growing Need for AI in Modern Pathology

Pathology plays a critical role in diagnosing diseases and guiding treatment decisions. However, rising patient volumes, shortages of skilled pathologists, and increasing diagnostic complexity are placing significant pressure on healthcare systems.

Download PDF Brochure

AI technologies are helping address these challenges by enhancing image analysis, automating repetitive tasks, and improving diagnostic accuracy. Deep learning models such as Convolutional Neural Networks (CNNs), Generative Adversarial Networks (GANs), and Recurrent Neural Networks (RNNs) are increasingly being used to analyze pathology images and support clinical workflows.

The rising prevalence of diagnostic errors and misdiagnoses is another major factor accelerating the adoption of AI-enabled pathology solutions. AI systems can identify subtle abnormalities that may be difficult for human observers to detect, thereby supporting more accurate and timely diagnoses.

Technological Innovations Driving Market Growth

Several technological developments are contributing to the rapid growth of the AI in pathology market. Among the most important are:

• Continuous advancements in CNN-based deep learning algorithms.
• Increasing adoption of whole slide imaging (WSI) in digital pathology.
• Expansion of AI-augmented telepathology platforms.
• Growing utilization of computational pathology techniques.
• Rising deployment of cloud-based AI pathology solutions.
• Increasing integration of multi-omics platforms for personalized medicine.

These innovations are enabling healthcare organizations to improve efficiency while delivering more precise and data-driven patient care.

Drug Discovery Segment Leads the Market

Based on use case, the drug discovery segment accounted for the largest share of the AI in pathology market in 2024 and is expected to witness the highest growth during the forecast period.

Pharmaceutical and biotechnology companies are increasingly leveraging AI-powered pathology tools to accelerate therapeutic development and improve research outcomes. AI algorithms can analyze vast amounts of histopathological data, helping researchers identify biomarkers, classify diseases, and discover novel treatment targets.

Several factors are supporting the growth of this segment:

• Rising R&D investments by pharmaceutical and biotechnology companies.
• Increasing adoption of high-throughput screening and imaging technologies.
• Growing application of AI in pathology image analysis.
• Demand for faster and more efficient drug development processes.

By reducing the time and cost associated with traditional drug discovery, AI is emerging as a valuable tool for next-generation therapeutics.

Image Analysis Emerges as the Largest Function Segment

Among various functions, the image analysis segment captured the largest share of the market in 2024.

Image analysis solutions are increasingly being used to automate tissue classification, identify disease patterns, quantify biomarkers, and support precision medicine initiatives. These systems help pathologists make faster and more consistent diagnoses while reducing manual workloads.

The dominance of this segment can be attributed to several factors:

• Growing emphasis on early disease detection.
• Rising demand for precision diagnostics.
• Integration of digital pathology technologies.
• Global shortage of trained pathologists.
• Increasing focus on personalized and targeted therapies.

As pathology laboratories continue their digital transformation, AI-driven image analysis is expected to remain a key area of investment.

Whole Slide Imaging and Digital Pathology Revolutionizing Diagnostics

Whole Slide Imaging (WSI) has become one of the most important enablers of AI adoption in pathology. WSI allows glass slides to be digitized into high-resolution images that can be analyzed using AI algorithms.

This capability is revolutionizing pathology by enabling:

• Remote consultations and telepathology.
• Automated image interpretation.
• Improved workflow efficiency.
• Enhanced collaboration among pathologists.
• Better data storage and retrieval capabilities.

The combination of WSI and AI is paving the way for computational pathology, where data-driven insights can significantly improve patient outcomes and clinical decision-making.

Europe Holds the Second-Largest Market Share

Regionally, Europe accounted for the second-largest share of the AI in pathology market in 2024.

The region's growth is being fueled by increasing healthcare digitization, favorable government initiatives, growing patient data volumes, and rising investments in AI technologies. Europe is also witnessing strong venture capital funding activities and increasing healthcare expenditure, further supporting market expansion.

Additionally, the growing elderly population and rising incidence of chronic diseases are creating substantial demand for advanced diagnostic solutions.

The presence of leading AI pathology companies and technology innovators across Europe is further strengthening the region's position in the global market.

Competitive Landscape

The AI in pathology market is characterized by the presence of several prominent players focused on innovation, strategic partnerships, and product development. Major companies operating in the market include:

• Koninklijke Philips N.V. (Netherlands)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Hologic, Inc. (US)
• Akoya Biosciences, Inc. (US)
• Aiforia Technologies Plc (Finland)
• Indica Labs Inc. (US)
• OptraScan (US)
• Ibex Medical Analytics Ltd. (Israel)
• Mindpeak GmbH (Germany)
• Tribun Health (France)

These companies are investing heavily in AI algorithms, digital pathology platforms, and cloud-based solutions to enhance diagnostic accuracy and streamline pathology workflows.

Future Outlook

The future of pathology is increasingly digital, intelligent, and data-driven. AI technologies are transforming how diseases are detected, classified, and treated while improving workflow efficiency across healthcare organizations.

As computational pathology, multi-omics integration, and whole slide imaging continue to evolve, AI-powered pathology solutions are expected to play a central role in precision medicine and drug discovery.

With the market anticipated to reach USD 347.4 million by 2030, AI in pathology is poised to redefine diagnostic practices and accelerate the transition toward smarter and more personalized healthcare.